Jan 3, 2018
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
C. A. Martin, C. Cullinane, L. Kirby, S. Abuhammad, E. J. Lelliott, K. Waldeck, R. J. Young, N. Brajanovski, D. P. Cameron, R. Walker, E. Sanij, G. Poortinga, R. D. Hannan, R. B. Pearson, R. J. Hicks, G. A. McArthur, K. E. Sheppard , International Journal of Cancer , DOI: 10.1002/ijc.31220
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are currently in clinical trials for the treatment of melanoma. We hypothesize that the timing of the addition of CDK4/6 inhibitors to the current BRAF and MEK inhibitor regime will impact...